Munich\/ Berlin \u2014 Berlin-based 3B Phar\u00admaceu\u00adti\u00adcals GmbH has signed an exclu\u00adsive license agree\u00adment with Novar\u00adtis Inno\u00adva\u00adtive Thera\u00adpies AG as licen\u00adsee. Under the agree\u00adment, Novar\u00adtis recei\u00adves world\u00adwide deve\u00adlo\u00adp\u00adment and commer\u00adcia\u00adliza\u00adtion rights for diagno\u00adstic and thera\u00adpeu\u00adtic appli\u00adca\u00adti\u00adons of parts of 3BP\u2019s FAP targe\u00adting peptide radio\u00adli\u00adgand tech\u00adno\u00adlogy. The tech\u00adno\u00adlogy targets fibro\u00adblast acti\u00adva\u00adtion protein (FAP), a promi\u00adsing ther\u00adano\u00adstic target due to its expres\u00adsion in a variety of cancers. In 3BP\u2019s radio\u00adli\u00adgand tech\u00adno\u00adlogy, the peptide is combi\u00adned with a radio\u00adac\u00adtive isotope that, depen\u00adding on the type of isotope, enables either imaging or thera\u00adpeu\u00adtic applications.<\/p>\n
Under the agree\u00adment, 3BP will receive an initial payment of $40 million and up to $425 million in deve\u00adlo\u00adp\u00adment, regu\u00adla\u00adtory and commer\u00adcial mile\u00adstone payments, in addi\u00adtion to tiered royal\u00adties on net sales.<\/p>\n
About 3BP 3BP is a long-stan\u00adding client of Ellen Berg\u00admann. The mandate has been in place since the company was foun\u00added in 2008. Ellen Berg\u00admann has parti\u00adcu\u00adlar exper\u00adtise in advi\u00adsing biotech and phar\u00admaceu\u00adti\u00adcal compa\u00adnies on complex licen\u00adsing and deve\u00adlo\u00adp\u00adment agree\u00adments, espe\u00adci\u00adally in the field of radio\u00adphar\u00admaceu\u00adti\u00adcals. She has successfully advi\u00adsed 3BP on previous licen\u00adsing and deve\u00adlo\u00adp\u00adment agree\u00adments, e.g. the prede\u00adces\u00adsor agree\u00adment to the current deal with Novar\u00adtis between 3BP and the US company Clovis Onco\u00adlogy Inc. and in the licen\u00adsing and rese\u00adarch agree\u00adment between 3BP and the Swiss phar\u00admaceu\u00adti\u00adcal company Debio\u00adph\u00adarm Inter\u00adna\u00adtio\u00adnal SA.<\/p>\n Advi\u00adsor 3B Phar\u00admaceu\u00adti\u00adcals: Green\u00adGate Part\u00adners Rechts\u00adan\u00adwalts\u00adge\u00adsell\u00adschaft mbH About Green\u00adGate Partners<\/strong> Munich\/ Berlin \u2014 Berlin-based 3B Phar\u00admaceu\u00adti\u00adcals GmbH has signed an exclu\u00adsive license agree\u00adment with Novar\u00adtis Inno\u00adva\u00adtive Thera\u00adpies AG as licen\u00adsee. Under the agree\u00adment, Novar\u00adtis recei\u00adves world\u00adwide deve\u00adlo\u00adp\u00adment and commer\u00adcia\u00adliza\u00adtion rights for diagno\u00adstic and thera\u00adpeu\u00adtic appli\u00adca\u00adti\u00adons of parts of 3BP\u2019s FAP targe\u00adting peptide radio\u00adli\u00adgand tech\u00adno\u00adlogy. The tech\u00adno\u00adlogy targets fibro\u00adblast acti\u00adva\u00adtion protein (FAP), a promi\u00adsing ther\u00adano\u00adstic target [\u2026]<\/p>\n","protected":false},"author":2,"featured_media":48486,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"wp_typography_post_enhancements_disabled":false,"footnotes":""},"categories":[886,1364,1366,1367,1368,1369,1371],"tags":[],"class_list":["post-48488","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-general-en","category-featured-en","category-news-en","category-lawyers-tax-advisors-auditors-en","category-lawyers-tax-consultants-auditors","category-investors","category-deals-en"],"yoast_head":"\n
\n<\/strong>
\n3B Phar\u00admaceu\u00adti\u00adcals rese\u00adar\u00adches and deve\u00adlops targe\u00adted radio\u00adphar\u00admaceu\u00adti\u00adcals that provide targe\u00adted and
\nperso\u00adna\u00adli\u00adzed approach to the treat\u00adment of cancer. Our pepti\u00addes and pepti\u00addo\u00admime\u00adtics represent
\nexcel\u00adlent tumor-speci\u00adfic targets and are linked via chela\u00adtion to thera\u00adpeu\u00adtic and diagnostic
\nradio\u00adiso\u00adto\u00adpes coupled via a chela\u00adting agent. As a leader in peptide disco\u00advery and opti\u00admiza\u00adtion, 3BP has built a tech\u00adno\u00adlogy plat\u00adform that spans from hit iden\u00adti\u00adfi\u00adca\u00adtion to early clini\u00adcal deve\u00adlo\u00adp\u00adment. www.3b-pharma.com<\/p>\n
\n<\/strong>
\nEllen Berg\u00admann, LL.M. (Lawyer, Partner)<\/p>\n
\nGreen\u00adGate Part\u00adners is a tech\u00adno\u00adlogy law firm with parti\u00adcu\u00adlar exper\u00adtise around tran\u00adsac\u00adtions and venture capi\u00adtal. From our offices in Berlin, Hamburg and Munich, expe\u00adri\u00aden\u00adced lawy\u00aders offer their clients first-class advice at eye level.<\/p>\n","protected":false},"excerpt":{"rendered":"